A Phase 3 interventional study of metreleptin and Placebo in Partial Lipodystrophy, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 31 sites in 9 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Chiesi Farmaceutici S.p.A. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase III, double-blind, placebo-controlled, safety and efficacy study of daily SC metreleptin in subjects with Partial Lipodystrophy.
This Phase 3, randomised, multicentre, double-blind, placebo-controlled study is designed to evaluate the safety and efficacy of once-daily subcutaneous metreleptin in participants with partial lipodystrophy and associated metabolic complications. The study compares metreleptin with placebo over a 12-month treatment period, followed by an extension phase. The primary objective is to assess the effect of metreleptin on key metabolic parameters, including glycaemic control and hypertriglyceridemia.
Secondary objectives include evaluation of safety, tolerability, additional metabolic outcomes, liver-related parameters, and patient-reported outcomes in this rare disease population.
Chiesi Farmaceutici S.p.A. is the lead sponsor of 185 studies on the registry; 22 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 11 (61%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
≥7% (at Visit 1 and Visit 3) and/or Fasting TGs ≥500 mg/dL (5.65 mmol/L, at Visit 1 and Visit 3)
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metreleptin \[Recombinant-methionyl human Leptin; r-metHuLeptin\] for daily injection is a sterile, white, solid lyophilised cake
Drug: metreleptin
Placebo for daily injection is a sterile, white, solid lyophilised cake
Drug: Placebo
Metreleptin is a recombinant human leptin analog that is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency
Placebo
Change from baseline to month 6 in HbA1c in subjects with partial lipodystrophy (PL)
To evaluate the efficacy (HbAa1c) of daily SC metreleptin treatment
Time frame: 6 months
Percent change from Baseline to month 6 in fasting TGs in subjects with partial lipodystrophy (PL)
To evaluate the efficacy (TGs) of daily SC metreleptin treatment
Time frame: 6 months
Safety analysis of AEs, AESIs, SAEs by treatment arm
To evaluate the safety of daily SC metreleptin treatment in subjects with PL
Time frame: 12 months
Change from baseline to months 9 and 12 in HbA1c in subjects with partial lipodystrophy (PL)
To assess the effect of metreleptin on HbA1c
Time frame: 12 months
Percent change from baseline to months 9 and 12 in fasting TGs in subjects with partial lipodystrophy (PL)
To assess the effect of metreleptin on TGs
Time frame: 12 months
Change from Baseline to each assessment time point in quality of life (QoL) in all subjects
To assess the effect of metreleptin on quality of life (QoL) in all subjects
Time frame: 12 months
Ran from Dec 2021 to primary completion in Jul 2026, 54 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metreleptin
Lipodystrophy, Partial, Acquired